Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 6 weeks (-7 to +14 days).~2. Healthy without obvious medical conditions that preclude the subject to be in the study as established by the medical history and physical examination.~3. Written informed consent obtained from 1 or 2 parents or legal guardian as per country regulations~Exclusion Criteria:~1. Previous vaccination against poliovirus.~2. Low birth weight (BW \<2,500 gm).~3. Multiple pregnancy (twins, triplets, etc.),~4. Any confirmed or suspected immunosuppressive or immunodeficient condition including human immunodeficiency virus (HIV) infection.~5. Family history of congenital or hereditary immunodeficiency.~6. Major congenital defects or serious uncontrolled chronic illness (neurologic, pulmonary, gastrointestinal, hepatic, renal, or endocrine).~7. Known allergy to any component of the study vaccines.~8. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections.~9. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~10. Acute severe febrile illness at day of vaccination deemed by the Investigator to be a contraindication for vaccination.~11. Member of the subject's household (living in the same house or apartment unit) who has received OPV vaccine in the last 3 months.~12. Subject who, in the opinion of the Investigator or sub-Investigator, is unlikely to comply with the protocol or is inappropriate to be included in the study for the safety or the benefit-risk ratio of the subject.

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- G1: Sanofi bOPV Control (Type: EXPERIMENTAL): 210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
- G2: Sanofi bOPV Control (Type: EXPERIMENTAL): 210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
- G3: Trivalent OPV Control (Type: EXPERIMENTAL): 100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
- G4: Sanofi bOPV, Sanofi IPV (Type: EXPERIMENTAL): 210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
- G5: Sanofi bOPV, Sanofi 2 IPV (Type: EXPERIMENTAL): 210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
- G6: Sanofi bOPV, GSK IPV (Type: EXPERIMENTAL): 50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
- G7: Sanofi bOPV, GSK 2 IPV (Type: EXPERIMENTAL): 190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
- G8: Sanofi bOPV, SII IPV (Type: EXPERIMENTAL): 50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
- G9: Sanofi bOPV, SII 2 IPV (Type: EXPERIMENTAL): 190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete